Ladenburg Thalmann Financial Services
http://www.ladenburg.comLadenburg Thalmann Financial Services, Inc. (AMEX: LTS) provides retail and institutional securities brokerage, investment banking, investment activities, and asset management services as well as equity research. In May of 2008, Ladenburg Thalmann acquired Punk Ziegel & Company to strengthen its trading, research, and investment banking departments. Ladenburg Thalmann is headquartered in Miami, FL.
View Older Stories View More Recent Stories
-
Form 13F-HR LADENBURG THALMANN FINAN For: Jun 30
-
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
-
CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
-
Oncolytics Biotech (ONCY) Prices Public Offering of Common Share and Warrants
-
Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
-
IZEA, Inc (IZEA) PT Lowered to $2.60 at Ladenburg Thalmann
-
Oncolytics Biotech (ONCY) Announces Public Offering of Common Shares and Warrants
-
Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants
-
Ladenburg Thalmann Downgrades Western Gas Partners (WES) to Neutral
-
Inpixon (INPX) Prices $4.8 Million Public Offering of Common Stock, Warrants
-
Inpixon Prices $4.8 Million Public Offering
-
Ladenburg Makes Investment In Newday Financial Technologies
-
WhiteHorse Finance (WHF) PT Lowered to $14.50 at Ladenburg Thalmann
-
Ladenburg Thalmann Starts Owl Rock (ORCC) at Buy
-
NovaBay Pharma (NBY) Prices 4.2M Shares Registered Direct Offering at $1/Sh
-
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
-
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
-
Stemline Therapeutics (STML) Prices 5M Share Common Offering at $15.25/Sh
-
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock
-
Form 8-K LADENBURG THALMANN FINAN For: Aug 08
-
Form 8-K LADENBURG THALMANN FINAN For: Aug 08
-
Form 10-Q LADENBURG THALMANN FINAN For: Jun 30
-
Ladenburg Reports Second Quarter 2019 Financial Results
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Athenex (ATNX) PT Raised to $28 at Ladenburg Thalmann
-
LiveXLive Media (LIVX) PT Lowered to $5.50 at Ladenburg Thalmann
-
Invitae Corporation (NVTA) PT Raised to $28.75 at Ladenburg Thalmann
-
ZAGG Incorporated (ZAGG) PT Lowered to $9 at Ladenburg Thalmann
-
Paysign Inc. (PAYS) PT Raised to $15 at Ladenburg Thalmann
-
Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
-
Ladenburg Thalmann Downgrades Capitala Finance (CPTA) to Neutral
-
Ladenburg Thalmann Upgrades New York Mortgage Trust (NYMT) to Buy
-
Digital Turbine (APPS) PT Raised to $8 at Ladenburg Thalmann
-
OFS Credit Company, Inc. Commences Rights Offering
-
Ladenburg Thalmann Upgrades OFS Capital (OFS) to Buy
-
Ladenburg Thalmann Downgrades Fidus Investment Corp (FDUS) to Neutral
-
Owl Rock Capital Corporation Announces Underwriters Fully Exercised the Overallotment Option
-
Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Ladenburg Thalmann Downgrades Oxford Square Capital Corp (OXSQ) to Neutral
-
Ladenburg Thalmann Downgrades Whiting Petroleum (WLL) to Neutral
-
Ladenburg Thalmann Upgrades United Therapeutics Corp. (UTHR) to Buy
-
Exicure Inc. (XCUR) Prices 27.5M Share Common Offering at $2/Sh; Announces Uplisting to Nasdaq Market
-
Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock
-
Ladenburg Thalmann Starts HyreCar Inc. (HYRE) at Buy
-
Newtek Business Services Corp. Prices a Public Offering of 5.75% Notes Due 2024
-
Newtek Business Services Corp. Prices a Public Offering of 5.75% Notes Due 2024
-
Gemphire Therapeutics (GEMP), NeuroBo Pharmaceuticals Announce Merger Agreement
-
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
-
Ladenburg Thalmann Downgrades Viveve Medical (VIVE) to Neutral

